Washington Takes Steps to Ease Medical Cannabis Rescheduling Access

Washington officials move on rescheduling access

That's the extent of what CannIntel can confirm. The report's headline is the only detail in the material reviewed at publication, and it doesn't name the agency, the official or the legal vehicle. It also doesn't say whether the action is a rule, guidance, a bill or a letter, and it gives no effective date.

We won't guess at those details. Until the underlying documents are in hand, this is best read as state-level policy activity, which is how the signal is categorized. We'll update this story when the agency and instrument are identified.

Still, the framing is worth tracking. Rescheduling has been a federal story for years, and states have mostly been spectators. A state-side move to help operators capture its benefits would shift who does the work.

Why the tax question drives the story

Moving marijuana to Schedule III would take it outside that provision. Licensed operators in states like Washington have long paid effective tax rates far above those of ordinary businesses, because they can't deduct ordinary expenses such as rent and payroll beyond cost of goods sold. That math is hard to argue with.

Rescheduling itself has been slow. The Department of Health and Human Services recommended Schedule III in 2023. The DEA published a proposed rule in May 2024, and the administrative hearing process that followed stalled. Operators have waited since.

A federal rule and a tax return are separate things, though. Between them sits documentation: license classifications, product categories and records showing what a business actually sells. State regulators control much of that paper trail. One plausible reading of Thursday's report is that Washington officials are working on that gap, but CannIntel hasn't confirmed it.

What operators and investors should watch

First, the agency. A rule from a licensing regulator carries different weight than a letter from a state tax office or a legislative resolution. Second, scope. The headline refers to medical marijuana businesses specifically. If any benefit is limited to medical licensees, adult-use operators could be left on the wrong side of a new line.

Third is the registration problem. Substances in Schedule III still sit inside the Controlled Substances Act, and state-licensed dispensaries don't hold the DEA registrations that federally regulated handlers need. Tax relief and regulatory compliance won't arrive together unless Congress or the DEA addresses it. Not yet.

Fourth is the federal clock. Any state mechanism is only as valuable as the DEA's final action, and operators shouldn't book 280E savings on a rule that hasn't been finalized. For full background on where the federal process stands, see the CannIntel topic hub on DEA rescheduling.

Watch for the primary document behind Thursday's report, which should show the agency, the legal instrument and whether adult-use operators are covered. Operators with Washington licenses should ask their tax advisers what that document changes, if anything, before the DEA acts.